NO933044D0 - Fremgangsmaate for behandling av osteoporose - Google Patents

Fremgangsmaate for behandling av osteoporose

Info

Publication number
NO933044D0
NO933044D0 NO1993933044A NO933044A NO933044D0 NO 933044 D0 NO933044 D0 NO 933044D0 NO 1993933044 A NO1993933044 A NO 1993933044A NO 933044 A NO933044 A NO 933044A NO 933044 D0 NO933044 D0 NO 933044D0
Authority
NO
Norway
Prior art keywords
procedure
treatment
treating osteoporosis
subject
phosphonate
Prior art date
Application number
NO1993933044A
Other languages
English (en)
Other versions
NO305581B1 (no
NO933044L (no
Inventor
Jocelyn Elaine Mcosker
Original Assignee
Norwich Eaton Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Norwich Eaton Pharma filed Critical Norwich Eaton Pharma
Publication of NO933044D0 publication Critical patent/NO933044D0/no
Publication of NO933044L publication Critical patent/NO933044L/no
Publication of NO305581B1 publication Critical patent/NO305581B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Removal Of Specific Substances (AREA)
NO933044A 1991-02-26 1993-08-26 Anvendelse av et benaktivt fosfonat i kombinasjon med et °strogenhormon, og preparat i enhetsdoseform for behandling av osteoporose NO305581B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66177791A 1991-02-26 1991-02-26
PCT/US1992/000854 WO1992014474A1 (en) 1991-02-26 1992-01-31 Methods for the treatment of osteoporosis

Publications (3)

Publication Number Publication Date
NO933044D0 true NO933044D0 (no) 1993-08-26
NO933044L NO933044L (no) 1993-08-26
NO305581B1 NO305581B1 (no) 1999-06-28

Family

ID=24655074

Family Applications (1)

Application Number Title Priority Date Filing Date
NO933044A NO305581B1 (no) 1991-02-26 1993-08-26 Anvendelse av et benaktivt fosfonat i kombinasjon med et °strogenhormon, og preparat i enhetsdoseform for behandling av osteoporose

Country Status (18)

Country Link
US (1) US6329354B1 (no)
EP (1) EP0573604B1 (no)
JP (1) JP3727332B2 (no)
KR (1) KR100240358B1 (no)
AT (1) ATE119777T1 (no)
AU (1) AU664368B2 (no)
CA (1) CA2101275C (no)
CZ (1) CZ282609B6 (no)
DE (1) DE69201725T2 (no)
DK (1) DK0573604T3 (no)
ES (1) ES2069424T3 (no)
HU (1) HU215124B (no)
IE (1) IE65963B1 (no)
NO (1) NO305581B1 (no)
NZ (1) NZ241717A (no)
RU (1) RU2113848C1 (no)
SK (1) SK90093A3 (no)
WO (1) WO1992014474A1 (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07504672A (ja) * 1992-03-21 1995-05-25 エンテック　ゲゼルシャフト　フュア　エンドクリノロギッシェ　テヒノロギー　エム．ベー．ハー． 更年期骨粗鬆症の処置に対するエストリオールの使用
WO1994009017A1 (en) * 1992-10-09 1994-04-28 The Upjohn Company Pyrimidine bisphosphonate esters and (alkoxymethylphosphinyl)alkyl phosphonic acids as anti-inflammatories
US6399592B1 (en) 1992-12-23 2002-06-04 Merck & Co., Inc. Bishphosphonate/estrogen synergistic therapy for treating and preventing bone loss
AU5953894A (en) * 1992-12-23 1994-07-19 Merck & Co., Inc. Bisphosphonate/estrogen therapy for treating and preventing bone loss
CA2162470C (en) * 1993-05-15 1998-06-16 Walter Preis Tablet with improved bioavailability containing dichloromethylenediphosphonic acid as the active substance
US5554601A (en) * 1993-11-05 1996-09-10 University Of Florida Methods for neuroprotection
KR100385697B1 (ko) * 1994-12-28 2003-08-21 가도르 에스. 에이. 올파드로네이트를포함하는골체량동화성조성물
DE19635883A1 (de) * 1996-09-04 1998-03-05 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit einer Östriol enthaltenden Wirkstoffkombination
US6376477B2 (en) 1996-11-25 2002-04-23 Merck & Co., Inc. Combination of an agent that binds to the androgen receptor and a bisphosphonic acid in the prevention and/or treatment of diseases involving calcium or phosphate metabolism
WO1998023274A1 (en) * 1996-11-25 1998-06-04 Merck & Co., Inc. Androgenic and bisphosphonic agents coadministered to treat diseases
US6692763B1 (en) * 1998-11-19 2004-02-17 The Regents Of The University Of California Methods for treating postmenopausal women using ultra-low doses of estrogen
AR013994A1 (es) * 1998-10-30 2001-01-31 Gador Sa Procedimiento y preparaciones que modulan selectivamente la funcion del osteoblasto para la prevencion y tratamiento de las osteopatias fragilizantes.
US6579860B1 (en) * 1998-12-25 2003-06-17 Toray Industries, Inc. Interleukin-6 production inhibitors
US6339078B1 (en) 1999-07-20 2002-01-15 University Of Florida Research Foundation, Inc. Methods of prevention and treatment of ischemic damage
US6326365B1 (en) 1999-07-20 2001-12-04 Apollo Biopharmaceutics, Inc. Methods of prevention and treatment of ischemic damage
US7335650B2 (en) 2000-01-14 2008-02-26 Sterix Limited Composition
US6653298B2 (en) 2000-01-14 2003-11-25 Sterix Limited Composition
US20040038946A1 (en) * 2001-04-27 2004-02-26 Wilson Lon J. Fullerene-based drugs targeted to bone
NZ584219A (en) * 2007-11-30 2012-03-30 Novartis Ag C2-c5-alkyl-imidazole-bisphosphonates
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
SI2459176T1 (en) 2009-07-31 2018-01-31 Gruenenthal Gmbh Crystallization process and bioavailability
US9340565B2 (en) 2010-11-24 2016-05-17 Thar Pharmaceuticals, Inc. Crystalline forms
WO2017208070A1 (en) 2016-05-31 2017-12-07 Grünenthal GmbH Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3553314A (en) 1968-12-23 1971-01-05 Procter & Gamble Oral compositions for calculus retardation
US3683080A (en) 1970-08-28 1972-08-08 Procter & Gamble Compositions for inhibiting anomalous deposition and mobilization of calcium phosphate in animal tissue
EP0088462A3 (en) * 1982-03-01 1984-06-06 The Procter & Gamble Company Anti-inflammatory and rheumatic composition containing organophosphonate and steroid
EP0381296B1 (en) * 1984-04-30 1994-11-30 THE PROCTER & GAMBLE COMPANY Kit for use in the treatment of osteoporosis
US4761406A (en) 1985-06-06 1988-08-02 The Procter & Gamble Company Regimen for treating osteoporosis
IL86951A (en) 1987-07-06 1996-07-23 Procter & Gamble Pharma Methylene phosphonoalkylphosphinates and pharmaceutical preparations containing them

Also Published As

Publication number Publication date
SK90093A3 (en) 1994-09-07
DE69201725D1 (de) 1995-04-20
AU664368B2 (en) 1995-11-16
CA2101275C (en) 1998-08-04
CZ175593A3 (en) 1994-04-13
DK0573604T3 (da) 1995-05-29
HUT66429A (en) 1994-11-28
KR100240358B1 (ko) 2000-02-01
EP0573604B1 (en) 1995-03-15
DE69201725T2 (de) 1996-04-18
AU1643392A (en) 1992-09-15
RU2113848C1 (ru) 1998-06-27
CZ282609B6 (cs) 1997-08-13
HU215124B (hu) 1998-09-28
JPH06505501A (ja) 1994-06-23
EP0573604A1 (en) 1993-12-15
HU9302407D0 (en) 1993-11-29
NO305581B1 (no) 1999-06-28
NO933044L (no) 1993-08-26
IE920584A1 (en) 1992-08-26
ES2069424T3 (es) 1995-05-01
NZ241717A (en) 1997-02-24
WO1992014474A1 (en) 1992-09-03
ATE119777T1 (de) 1995-04-15
IE65963B1 (en) 1995-11-29
CA2101275A1 (en) 1992-08-27
US6329354B1 (en) 2001-12-11
JP3727332B2 (ja) 2005-12-14

Similar Documents

Publication Publication Date Title
NO933044D0 (no) Fremgangsmaate for behandling av osteoporose
RU93054017A (ru) Способ лечения остеопороза, композиция для лечения остеопороза, применение активно действующего на кости фосфоната и эстрогенного гормона для лечения остеопороза
ATE105482T1 (de) Behandlung von krebs mit somatostatin und mit analogen davon.
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
ZA967626B (en) Lipid extract having anti-inflammatory activity.
DE69218624D1 (de) Behandlung von peridontalkrankheiten mit alendronat
ES2179473T3 (es) Composiciones que contienen capsaicina o analogos de capsaicina y un anestesico local.
DE69736745D1 (de) Verfahren zur behandlung von prostaterkrankungen unter verwendung von vitamin-d-formulierungen mit verzögerter und/oder verlängerter wirkstofffreigabe
ATE218350T1 (de) Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen
ATE161423T1 (de) Verwendung von phosphinate zur behandlung der osteoporose
ATE125706T1 (de) Diphosphonate enthaltende pharmazeutische zusammensetzungen zur behandlung von arthrosis.
ES2114851T3 (es) Utilizacion de composiciones de liberacion sostenida que contienen gnrh, lhrh o derivados de las mismas.
DE69420776T2 (de) Idebenone-haltige Zusammensetzungen zur Behandlung von M. Alzheimer
ATE88633T1 (de) Verwendung von bestimmten calcium-citrate-malaten zur herstellung einer pharmazeutischen zubereitung fuer die behandlung von osteoporose.
EP0515434A4 (en) Method for treating intestinal diseases
DE69924483D1 (de) Kombinationstherapie zur behandlung von tumoren
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
DE69124382T2 (de) Authentischen igf-1 und hypokalorische menge von nährstoffen enthaltendes produkt und dessen verwendung zur behandlung kataboler zustände
MX9605327A (es) Uso de ciertos derivados de acido metanbisfosfonico para prevenir el aflojamiento de las protesis y la emigracion de las protesis.